"The Health Kick" podcast with Tim Boreham
Dear Investors,
Anatara Lifesciences CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead's new podcast series, "The Health Kick".
Anatara Lifesciences: Standing out in the gut health market, solving scours in livestock and the future of antibiotics in the food chain
In the interview, Steve discusses:
- Anatara's journey to today and its dual opportunities in human and animal gut health
- The significant unmet need for complementary medicines in the treatment of irritable bowel syndrome and inflammatory bowel disease
- How Anatara's Gastrointestinal ReProgramming (GaRP) dietary supplement unique approach addresses all three significant factors in chronic bowel conditions - microbiome dysbiosis, inflammation and mucosal damage
- Recent successful completion of GaRP's preclinical program, with statistically significant efficacy data from its in vivo animal studies and further positive in vitro proof of concept data
- The upcoming human clinical trial for GaRP and in parallel, the preparation of a licencing package to approach potential partner companies in 2020
- The next step's for partnering the Company's anti-diarrhoeal product, Detach®, in global markets and other livestock species
- Antimicrobial resistance is one of the greatest threats to mankind and how Detach® will help reduce in the use of antibiotics in livestock
Listen to the podcast interview here.
On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.
For further information on Anatara Lifesciences, click here for our latest Corporate Fact Sheet.
|
